CAPSTONE HEALTH SERVICES FOUNDATION PC

850 5TH AVE E

Articles

For Multiple Myeloma Patients, Convenience Now an Important Factor in the Treatment Equation

December 20, 2022

The Covid-19 pandemic revealed the advantages of treatment that involved fewer in-person office visits, according to research presented at American Society of Hematology meeting earlier this month. Researchers also saw a notable increase in the use of Darzalex (daratumumab).

Bispecific Antibody Treatments for Multiple Myeloma Are on Their Way

November 15, 2022

Johnson & Johnson’s Tecvayli (teclistamab-cqyv) has been approved by the FDA, and Pfizer’s elranatamab received breakthrough status that should speed its approval. Bispecific antibodies may be a bridge to CAR-T treatments or an alternative to them.